468 related articles for article (PubMed ID: 25308632)
1. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
Iorio R; Damato V; Alboini PE; Evoli A
J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in AChR subtype of myasthenia gravis: systematic review.
Di Stefano V; Lupica A; Rispoli MG; Di Muzio A; Brighina F; Rodolico C
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):392-395. PubMed ID: 32098874
[TBL] [Abstract][Full Text] [Related]
3. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
4. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
5. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
6. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.
Stieglbauer K; Pichler R; Topakian R
J Neurol Sci; 2017 Apr; 375():241-244. PubMed ID: 28320139
[TBL] [Abstract][Full Text] [Related]
7. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study.
Castiglione JI; Rivero AD; Barroso F; Brand P; Lautre A; Kohler AA
J Clin Neuromuscul Dis; 2022 Sep; 24(1):18-25. PubMed ID: 36005470
[TBL] [Abstract][Full Text] [Related]
11. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
Sudulagunta SR; Sepehrar M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Sathyanarayana D; Gummadi S; Burra HK
Ger Med Sci; 2016; 14():Doc12. PubMed ID: 27790079
[No Abstract] [Full Text] [Related]
12. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
13. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
[TBL] [Abstract][Full Text] [Related]
14. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
[TBL] [Abstract][Full Text] [Related]
15. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
[TBL] [Abstract][Full Text] [Related]
16. [Rituximab for the treatment of generalised myasthenia gravis: experience in clinical practice].
Martínez-Monte E; Gascón-Giménez F; Domínguez-Morán JA; Láinez-Andres JM
Rev Neurol; 2021 Nov; 73(12):416-420. PubMed ID: 34877644
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.
Marino M; Bartoccioni E; Alboini PE; Evoli A
Ann N Y Acad Sci; 2018 Feb; 1413(1):41-48. PubMed ID: 29369382
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
Jing S; Song Y; Song J; Pang S; Quan C; Zhou L; Huang Y; Lu J; Xi J; Zhao C
J Neuroimmunol; 2017 Oct; 311():14-21. PubMed ID: 28789841
[TBL] [Abstract][Full Text] [Related]
20. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]